Therapies

Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact

1 month ago   |   By Xconomy

Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases, the partners are expanding their pact to bleeding disorders. The deal announced Monday covers the development of potential treatments for hemophilia, which stems from genetic mutations that lead to insufficient levels of blood clotting proteins. The revised alliance covers the joint development of potential treatments for both hemophilia A and B. Regeneron also gains rights to discover and develop potential therapies addressing an...
Read more ...

 


Search by Tags

   Therapies      Protein      Therapeutics      Research      R&D      Pharmaceutical      Genetics      Pharmaceuticals      Boston blog main      Boston top stories      National blog main      National top stories      New York      New York blog main      New York top stories      BioMarin Pharmaceutical      Biotech      Clinical trials      CRISPR      Cas9      Deals      Gene editing      Gene Therapy      Hemophilia A      Hemophilia B      Intellia Therapeutics      John Leonard      Life Sciences      Patisiran      Pfizer      Regeneron Pharmaceuticals      RNA Interference      Sangamo Therapeutics      Transthyretin amyloidosis  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far-enough to pay $55 million to add multiple sclerosis and neuroinflammation... Read more ...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination...

The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period

The 2020 National Xconomy Awards - celebrating the best in biotech innovation and entrepreneurship - just got bigger! We're excited to announce the expansion of the 2020... Read more ...

Jr Lab Technician - eMolecules, Inc - San Diego, CA

With 6+ million products from 200+ suppliers, eMolecules is the global leader in research compounds with 9 of the 10 largest pharmaceutical companies and 4 of... $15 an... Read more ...

Improving plant drought tolerance and growth under water limitation through...

Summary Agriculture is by far the biggest water consumer on our planet, accounting for 70 percent of all freshwater withdrawals. Climate change and a growing world population... Read more ...

Glycan Engineering Reveals Interrelated Effects of Terminal Galactose and...

ABSTRACT Antibody‐dependent cell‐mediated cytotoxicity has been identified as one of the potentially critical effector functions underlying the clinical efficacy of some... Read more ...

Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant...

CARLSBAD, Calif.--- $LCTX AMD-Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced... Read more ...

Incensed Applied Therapeutics vows to end 'criminal activity' from short report

Incensed Applied Therapeutics vows to end 'criminal activity' from short report badams Mon, 07/06/2020 - 07:31 Read more ...

Mirati Therapeutics: Clinical Trial Manager: 2020-85

Mirati Therapeutics: The Clinical Trial Manager provide trial operational oversight of CROs and vendors. This role also ass San Diego, CA, United States ... Read more ...

An epistatic interaction between pre-natal smoke exposure and socioeconomic...

Asthma is one of the leading chronic illnesses among children in the United States. Asthma prevalence is higher among African Americans compared to European Americans... Read more ...

A programmable CRISPR/Cas9-based phage defense system for Escherichia coli BL21

Escherichia coli BL21 is arguably the most popular host for industrial production of proteins, and industrial fermentations are often plagued by phage infections. The... Read more ...